PTC Therapeutics Acquires BLA-Stage Fabry Disease Gene Therapy ST-920 for Up to $211M

summarizeSummary

PTC Therapeutics is acquiring ST-920, a BLA-stage gene therapy for Fabry disease, for up to $211 million, enhancing its rare disease pipeline and leveraging existing commercial capabilities.

check_boxKey Events · M&A and Partnerships · PTCT

• Acquisition of ST-920

  PTC Therapeutics was selected as the winning bidder to acquire ST-920, a BLA-stage one-time administered AAV gene therapy product candidate for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction.

• Financial Terms

  The acquisition includes an upfront payment of $111 million and up to $100 million in contingent milestone payments tied to accelerated and traditional FDA approvals. The total potential cost is $211 million.

• Strategic Rationale

  The acquisition leverages PTC's existing global rare disease commercial infrastructure to accelerate short- and intermediate-term revenue growth, with the potential for significant return on investment without the need for new development or commercial build.

• Regulatory Pathway

  A rolling Biologics License Application (BLA) submission to the FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026, with potential for commercial launch in 2027. ST-920 has received Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations.

auto_awesomeAnalysis · PTCT · Life Sciences

PTC Therapeutics is strategically expanding its rare disease portfolio by acquiring ST-920, a late-stage gene therapy for Fabry disease, from a bankruptcy auction. This acquisition, valued at up to $211 million, brings a near-market asset that leverages PTC's existing commercial infrastructure and is expected to contribute to revenue growth without impacting the company's cashflow break-even target. This follows recent strong Q2 results and a convertible notes offering, indicating a solid financial position for such a move.